Announcements

1 October 2025
2024 MDPI Top 1000 Reviewers


We are honored to recognize the 2024 MDPI Top 1000 Reviewers—scholars whose exemplary commitment to rigorous and constructive peer review is vital in upholding the highest standards of academic publishing.

Selected from a distinguished pool of 215,000 reviewers from 65 countries and regions worldwide, these honorees stand out for their exceptional expertise, diligence, and dedication to advancing research through timely and thoughtful reviews. Their constructive and impartial feedback ensures the publication of high-quality, impactful research, while their timely reviews facilitate swift revisions and faster publication of innovative work.

Peer review is the invisible foundation of academic progress. With gratitude and respect, we celebrate these 1000 scholars who made that foundation stronger in 2024. We respected all privacy preferences, with part of nominees opting for limited attribution.

The names of these reviewers are listed below in alphabetical order by first name:

Abbas Yazdinejad

Hanane Boutaj

Ophir Freund

Abdessamad Belhaj

Hany H. Arab

Oscar De Lucio

Abdolreza Jamilian

Hao Zang

Otilia Manta

Abdul Waheed

Hatem Amin

Panagiotis D. Michailidis

Abiel Aguilar-González

Henry Alba

Panagiotis Simitzis

Adina Santana

Hiroyuki Noda

Paola Prete

Aditya Velidandi

Hitoshi Tanaka

Paolo Trucillo

Adrian Stancu

Horst Lenske

Patricia Kara De Maeijer

Adriana Borodzhieva

Hossein Azadi

Patrícia Pires

Adriana Cristina Urcan

Houlin Yu

Paulo Schwingel

Adriano Bressane

Huaifu Deng

Pavel Loskot

Agbotiname Imoize

Huamin Jie

Pedro García-Ramírez

Agustin L. Herrera-May

Hugo Lisboa

Pedro Pablo Zamora

Ahmed Arafa

Igor L. Zakharov

Pedro Pereira

Ahmet Cagdas Seckin

Igor Litvinchev

Pei-Hsun Wang

Ailton Cesar Lemes

Igor Vujović

Pellegrino La Manna

Akash Kumar

Ildiko Horvath

Petar Ozretić

Akihiko Murayama

Ilya A. Khodov

Petko Petkov

Alain E. Le Faou

Ilya Zavidovskiy

Petr Komínek

Alain Massart

Imran Ali Lakhiar

Petras Prakas

Alejandro Plascencia

Ines Aguinaga-Ontoso

Petro Pukach

Aleksandar Ašonja

Ioan Hutu

Petru Alexandru Vlaicu

Aleksandra Głowacka

Ioan Petean

Phil Chilibeck

Aleksandra Nesić

Irena M. Ilic

Pia Lopez-Jornet

Alessio Ardizzone

Isaac Lifshitz

Pietro Geri

Alessio Faccia

Ismael Cristofer Baierle

Pingfan Hu

Alexander E. Berezin

I-Ta Lee

Piotr Cyklis

Alexander Lykov

Itzhak Aviv

Piotr Gauden

Alexander Robitzsch

Iustinian Bejan

Piotr Gawda

Alexandre Landry

Ivan Matveev

Pradeep Kumar Panda

Alexey Chubarov

Ivan Pavlenko

Pradeep Varadwaj

Alexey Morgounov

Ivana Mitrović

Presentación Caballero

Alexis Rodríguez

Iyyakkannu Sivanesan

Pu Xie

Alfredo Silveira De Borba

Jacek Abramczyk

Qingchao Li

Ali Hashemizdeh

Jacques Cabaret

Qinghua Qiu

Alison De Oliveira Moraes

Jaime A. Mella-Raipán

Qingwei Chen

Aliyu Aliyu

Jaime Taha-Tijerina

Radoslaw Jasinski

Alok Dhaundiyal

James Chun Lam Chow

Radu Racovita

Álvaro Antón-Sancho

James Chung-Wai Cheung

Rafael Galvão De Almeida

Amit Ranjan

James O. Finckenauer

Rafael Melo

Amritlal Mandal

Jan Cieśliński

Rafal Kukawka

Ana Isabel Roca-Fernández

Ján Moravec

Rafał Watrowski

Ana Tomić

Jarbas Miguel

Raffaele Pellegrino

Anas Alsobeh

Jaroslav Dvorak

Rajender Boddula

Anastasios Karayiannakis

Jarosław Przybył

Ralf Hofmann

Andre Luiz Costa

Jasenka Gajdoš Kljusurić

Ran Wang

Andrea Bianconi

Jasmina Lukinac

Ranko S. Romanić

Andrea Sonaglioni

Jawad Tanveer

Ratna Kishore Velamati

Andrea Tomassi

Jean Carlos Bettoni

Rebecca Creamer

Andrés Fernando Barajas Solano

Jennie Golding

Reggie Surya

Andrés Novoa

Jerzy Chudek

Rehan Siddiqui

Andreu Comas-Garcia

Jhih-Rong Liao

Renato Maaliw

Andrew Lane

Jiachen Li

Reuven Yosef

Andrew Lothian

Jianzhu Liu

Ricardo García-León

Andrew Sortwell

Jiaquan Yu

Richard Murray

Andrius Katkevičius

Jibing Chen

Robert Boyd

Andromachi Nanou

Jie Gao

Robert H. Eibl

Andrzej Kielian

Jie Hua

Robert James Crammond

Andrzej Kozłowski

Jill Channing

Robert Oleniacz

Andrzej Zolnowski

Jinfeng Li

Roberto Passera

Ángel Josabad Alonso-Castro

Jinle Xiang

Rodolpho Fernando Vaz

Ángel Llamas

Jinliu Chen

Rodrigo Galo

Angelo Ferlazzo

Jinyao Lin

Roger E. Thomas

Angelo Marcelo Tusset

Jinyu Hu

Roger W. Bachmann

Anil K. Meher

Jiří Remr

Rogério  Leone Buchaim

Animesh Kumar Basak

Jiying Liu

Roman Trach

Anita Silvana Ilak Peršurić

João Everthon Da Silva Ribeiro

Roman Trochimczuk

Anna Kharkova

Joao Pessoa

Romil Parikh

Anna Lenart-Boroń

Joaquim Carreras

Romina Fucà

Anna Piotrowska

John Adams Sebastian

Ronald Nelson

Anne Anderson

John Van Boxel

Rosie Yagmur Yegin

Antiopi-Malvina Stamatellou

Jonathan Puente-Rivera

Roxana Lucaciu

Antonia Kondou

Jordi-Roger Riba

Rui Sales Júnior

Antonio Miguel Ruiz Armenteros

Jorge De Andres-Sanchez

Rui Vitorino

Anusorn Cherdthong

Jorge Guillermo Diaz Rodriguez

Ruo Wang

Aram Cornaggia

Jorge Luis Zambrano-Martinez

Ryoma Michishita

Ariana Saraiva

José F. Fontanari

Sabina Necula

Ariel Soares Teles

José Felipe Orzuna-Orzuna

Sabina Umirzakova

Aristeidis Karras

José Francisco Segura Plaza

Said EL-Ashker

Arnaud Dragicevic

José Luis Díaz

Saïf Ed-Dı̂n Fertahi

Artem Obukhov

José Luis Rivera-Armenta

Salvatore Romano

Arvind Kumar Shukla

Jose M. Miranda

Sándor Beszédes

Arvind Negi

Jose M. Mulet

Santiago Lain

Athanasios A. Panagiotopoulos

Jose Navarro-Pedreño

Sara Black Brown

Augustine Edegbene

José Pedro Cerdeira

Sarat Chandra Mohapatra

Aunchalee Aussanasuwannakul

Jouni Räisänen

Sarunas Grigaliunas

Aurel Maxim

Jui-Yang Lai

Saša Milojević

Barbara Symanowicz

Juliana Fernandes

Sawsan A. Zaitone

Bartosz Płachno

Julio Plaza Díaz

Scott E. Hendrix

Bela Kocsis

Juliusz Huber

Seong-Gon Kim

Benedetto Schiavo

Jun Liu

Sergii Babichev

Bernhard Koelmel

Junyu Chen

Sergio Da Silva

Bhupendra Prajapati

Karan Nayak

Sérgio Felipe

Bierng-Chearl Ahn

Karel Allegaert

Sergio Guzmán-Pino

Bo Zhou

Katarina Aškerc Zadravec

Seyed Kourosh Mahjour

Bohong Zhang

Katarzyna Kubiak-Wójcicka

Seyed Masoud Parsa

Bonface Ombasa Manono

Katarzyna Peta

Shedrach Benjamin Pewan

Bozhidar Stefanov

Katarzyna Tandecka

Shehwaz Anwar

Brach Poston

Katherine Bussey

Shengwen Tang

Byeong Yong Kong

Katsuya Ichinose

Shih-Lin Lin

Caio Sampaio

Kazuharu Bamba

Shilong Li

Caius Panoiu

Kazuhiko Kotani

Shing-Hwa Liu

Caiyun Wang

Kazuhiko Nakadate

Shu Yuan

Calin Mircea Gherman

Keigi Fujiwara

Shuohong Wang

Camelia Delcea

Keith Rochfort

Shuolin Xiao

Cardellicchio Angelo

Kenneth Waters

Shuping Wu

Carlos Alberto Ligarda Samanez

Keren Dopelt

Sihui Dong

Carlos Almeida

Kira E. Vostrikova

Sławomir Rabczak

Carlos Balsas

Kit Leong Cheong

Sojung Kim

Carlos López-de-Celis

Konstantinos Vergos

Songli Zhu

Carlos Marcuello

Koyeli Girigoswami

Soonhee Hwang

Carlos Pascual-Morena

Krzysztof R. Karsznia

Soo-Whang Baek

Carlos Torres-Torres

Krzysztof Szwajka

Soufiane Haddout

Casey Watters

Krzysztof Wołk

Sousana Papadopoulou

Castillo Castillo

Kumar Ganesan

Spiros Paramithiotis

Changmin Shi

Lan Lin

Spyridon Kaltsas

Chao Chen

László Radócz

Srecko Stopic

Chao Gu

Laurent Donzé

Srinivasan Sathiyaraj

Chao Zhang (China)

Lei He

Stefano Mancin

Chao Zhang (Singapore)

Lei Huang

Subhadeep Das

Chellapandian Maheswaran

Leonard-Ionut Atanase

Sumedha Nitin Prabhu

Cheonshik Kim

Leonardo Henrique Dalcheco Messias

Sushant K. Rawal

Chia Hung Kao

Leonie Brummer

Svetoslav Todorov

Chiachung Chen

Levon Gevorkov

Szymon Janczar

Chiara Cinquini

Li Fu

Tadeusz Kowalski

Chieh-Chih Tsai

Lidija Hauptman

Tadeusz Sierotowicz

Christian Rojas

Lin-Fu Liang

Taha Koray Sahin

Chu Zhang

Ling Yang

Tahir Cetin Akinci

Chuanyu Sun

Lingli Deng

Takuo Sakon

Chun-Wei Yang

Ljubica Kazi

Tamara Lazarević-Pašti

Claudia Bita-Nicolae

Lotfi Boudjema

Tao Zhang

Constant Mews

Louis Moustakas

Taras P. Pasternak

Cristian Vacacela Gomez

Luca Ulrich

Tarek Eldomiaty

Cristiano Matos

Luis Adrian De Jesús-González

Taro Urase

Cristian-Valeriu Stanciu

Luis Alfonso Díaz-Secades

Tenzer Robert

Cristóbal Macías Villalobos

Luis Filipe Almeida Bernardo

Thawatchai Phaechamud

Dalia Calneryte

Luis Nestor Apaza Ticona

Thomas Michael

Daniel Hernandez-Patlan

Luis Puente-Díaz

Tiberiu Harko

Daniele Ritelli

Luiz Antonio Alcântara Pereira

Timea Claudia Ghitea

Daniel-Ioan Curiac

Łukasz Rakoczy

Timothy John Mahony

Daniil Olennikov

Łukasz Szeleszczuk

Timothy Omara

Daodao Hu

Maciej Kruszyna

Tomasz Hikawczuk

Daqin Guan

Magdalena Jaciow

Tomasz M. Karpiński

Daria Chudakova

Maha Nasr

Tomasz Trzepiecinski

Daria Mottareale-Calvanese

Maharshi Bhaswant

Triantafyllos Didangelos

Dariusz Dziki

Maksim Zavalishin

Tsvetelin Zaevski

Dariusz Gozdowski

Małgorzata Jeleń

Ulrich J. Pont

David Kieda

Man Fai Leung

Vadim Kramar

David Luviano-Cruz

Manickam Minakshi

Vagner Lunge

Da-Zhi Sun

Marcel Sari

Valério Monteiro-Neto

Debra Wetcher-Hendricks

Marcello Iasiello

Van Giap Do

Demin Cai

Marco Limongiello

Van-An Duong

Dennis Dieks

Marco Zucca

Vanni Nicoletti

Deokho Lee

Marconi Batista Teixeira

Vasilios Liordos

Deyu Li

Marcos Vinícius Da Silva

Vedran Mrzljak

Diego Romano Perinelli

Marek Cała

Vicente Romo Pérez

Dimitris Tatsis

Maria G. Ioannides

Victor-Alexandru Briciu

Dirceu Ramos

Maria João Lima

Viktor V. Brygadyrenko

Dmitrii Pankin

Maria Kantzanou

Vinícius Silva Belo

Dmitriy Yambulatov

Maria Leonor Abrantes Pires

Violeta Popovici

Dmitry Kultin

Mariana Buranelo Egea

Viorel Dragos Radu

Dongwei Di

Mariana Magalhães

Viswas Raja Solomon

Dorota Formanowicz

Marija Strojnik

Viviani Oliveira

Dragan Marinkovic

Marijn Speeckaert

Vlad Rotaru

Drazenko Glavic

Marina G. Holyavka

Vladica Stojanović

Duguleana Mihai

Marina Gravit

Volodymyr Hrytsyk

Dušan S. Dimić

Mario Cerezo Pizarro

Volodymyr Ponomaryov

E Terasa Chen

Mario Ganau

Waldemar Studziński

Edoardo Bucchignani

Mariusz Ptak

Wanming Lin

Eduard Zadobrischi

Marlen Vitales-Noyola

Waseem Jerjes

Edwin Villagran

Marta Forte

Wei-Chieh Lee

Eitan Simon

Martha Rocío Moreno-Jimenez

Weiming Fang

Elena Chitoran

Marwan El Ghoch

Weiren Luo

Elena Marrocchino

Marzena Włodarczyk-Stasiak

Weiwei Jiang

Elisabeta Negrău

Massimiliano Schiavo

Wenan Yuan

Elisavet Bouloumpasi

Massoomeh Hedayati Marzbali

Wenguang Yang

Elochukwu Ukwandu

Mateusz Rozmiarek

Wenluan Zhang

Emil Smyk

Matt Smith

Wiesław Przygoda

Emilio Bucio

Matteo Riccò

Wilian Paul Arévalo Cordero

Emmanouil Karampinis

Matthias Müller

Wilian Pech-Rodríguez

Ericsson D. Coy-Barrera

Mauro Lombardo

Wislei R. Osório

Eugeniusz Koda

Md. Ataur Rahman

Wi-Young So

Ewa Chomać-Pierzecka

Md. Biddut Hossain

Wojciech Sałabun

Ewa Tomaszewska

Meisam Abdollahi

Wojciech Zabierowski

Ezhaveni Sathiyamoorthi

Meng-Hwan Lee

Xiaofei Du

Fabio Corti

Meng-Yao Li

Xiaolong Ji

Fahmi Zairi

Meysam Keshavarz

Xiaomin Xu

Fanzhi Kong

Michael Eisenhut

Xiaoshuang Ma

Fasih Ullah Haider

Michael Gerlich

Xiaoying Liu

Fayez Tarsha-Kurdi

Mihaela Brindusa Tudose

Xiao-Yong Wang

Fekete Mónika

Mihaela Niculae

Xinming Zhang

Felipe Jiménez

Mihaela Tinca Udristioiu

Xinqiao Liu

Feng Wen

Mihaela Toderaş

Xinqing Xiao

Ferdinando Di Martino

Mihai Crenganis

Xuechen Zheng

Fernanda Tonelli

Mika Simonen

Xueming Zhang

Fernando Lessa Tofoli

Milan Toma

Xuezhen Wang

Fernando Viadero-Monasterio

Miloš Lichner

Xuguang Cai

Fethi Ouallouche

Milos Seda

Yair Wiseman

Flavio Arroyo

MIloš Zrnić

Yang Xu

Flor H. Pujol

Min Xia

Yangwon Lee

Florin Dumitru Bora

Mina Tadros

Yanhong Peng

Florin Nechita

Mingming Ge

Yao Ni

Francesco Di Bello

Mingren Shen

Yaoxiang Li

Francesco Galluzzo

Mircea Neagoe

Yasushige Shingu

Francisco Haces Fernandez

Mirela-Fernanda Zaltariov

Yaswanth Kuthati

Francisco Rego

Mirjana Ljubojević

Yaxin Liu

Francisco Solano

Mirko Stanimirović

Ygor Jessé Ramos

Frédéric Muttin

Mirza Pojskić

Yi Xu

Fredrick Eze

Modesto Pérez-Sánchez

Yifan Zhao

Gabriel Milan

Mohammad Ali Sahraei

Yih Jeng

Gabriel Zazeri

Mohammad Javad Maghsoodi Tilaki

Yiyang Chen

Galina Ilieva

Mohammad Qneibi

Yoichi Shiraishi

Gary Van Vuuren

Mohammed Gamal

Yong Hwan Kim

Gennadiy Kolesnikov

Mohammed Sayed

Yongqi Yin

George E. Mustoe

Mounia Tahri

Young-joo Ahn

George Lazaroiu

Muhammad Ahsan Asghar 

Yousi Fu

George Xiroudakis

Muhammad N. Mahmood

Yuan Meng

Georgiy Gamov

Muhammad Syafrudin

Yuefei Zhuo

Gerald Cleaver

Muhammed Yildirim

Yugang He

Ghassan Ghssein

Murilo E. C. Bento

Yuliia Trach

Gian Mario Migliaccio

Muthuraj Arunpandian

Yuliya Semenova

Giancarlo Trimarchi

Narcis Eduard Mitu

Yuri Jorge Peña-Ramirez

Gianmarco Ferrara

Naser Alsharairi

Yuri Konstantinov

Giovanni Tesoriere

Natale Calomino

Yusheng Xiang

Giuseppe Brunetti

Natanael Karjanto

Yutaka Ohsedo

Giuseppe Di Martino

Nataša Nastić

Zaihua Duan

Giuseppe Losurdo

Naveed Ahmad

Zelaya-Molina Lily Xochilt

Giuseppina Uva

Nebojsa Pavlovic

Zenon Pogorelić

Glauber Cruz

Neli Milenova Vilhelmova

Zhang Ying

Glenn Morrison

Nguyen Dinh-Hung

Zhanni Luo

Gloria Cerasela Crisan

Nguyen Quoc Khuong

Zhao Ding

Gordana Wozniak-Knopp

Nicola Magnavita

Zhengmao Li

Gordon Alderink

Nicoleta Dospinescu

Zhengwei Huang

Grazia Giuseppina Politano

Nicoletta Cera

Zhidong Zhou

Grigorios L. Kyriakopoulos

Nidhi Puranik

Zhijun Li

Grzegorz Woroniak

Nikita Osintsev

Zhixiong Lu

Grzegorz Zieliński

Nikita V. Martyushev

Zhizhong Zhang

Guadalupe Gabriel Flores-Rojas

Nikola Stanisic

Zhong-Gao Jiao

Guangnian Xiao

Nilakshi Barua

Zia Muhammad

Guanxi Yan

Nobuo Funabiki

Žiga Laznik

Guoyou Zhang

Octavian Vasiliu

Zigmantas Gudžinskas

Gustavo Henrique Nalon

Oguzhan Der

Zishan Ahmad

Hai-yu Ji

Oimahmad Rahmonov

Zivan Gojkovic

Hamza Faraji

Olga Morozova

Zoran Mijić

Hamza Sohail

Onur Dogan

Zsuzsanna Bacsi

30 September 2025
Nobel Prize — The Science Behind the Prize


Nobel Prizes are the world’s most prestigious recognition of scientific breakthroughs, honoring discoveries that push the boundaries of knowledge and reshape entire fields. They bring into the public eye researchers whose work might otherwise remain known only within specialized circles.

For many, winning a Nobel Prize is a surreal experience. Laureates often describe a mix of joy, humility, reflection, and gratitude for the teams and collaborators whose contributions made the achievement possible. Behind every Nobel-winning idea lies years of careful, incremental work—a process that often goes unseen.

When Prof. Steven Weinberg won the Nobel Prize in Physics in October 1979, his wife Louise, a legal scholar, reminded him to keep doing the ordinary hard work of science, joking: “Now you have to write some unimportant papers.” True to form, Weinberg continued to push the boundaries of our understanding of the Universe, showing that curiosity and dedication extend far beyond the moment of recognition (Hofmann 2025: https://www.mdpi.com/2073-8994/17/6/840).

Discover the science behind the world’s most transformative ideas

Over the years, dozens of Nobel laureates have published their work with MDPI, entrusting our open access journals to disseminate their findings to a global audience. As of 2024, more than 40 laureates have contributed over 115 articles across 35 journals, ranging from pioneering research on microRNAs and mRNA therapeutics, to fundamental insights in theoretical physics, and advances in structural biology.

We regularly spotlight how Nobel Prize–winning research intersects with the contributions of our authors. This not only celebrates the achievements of the laureates, but also underscores the role of open access in ensuring that transformative science reaches the widest possible audience.

On this page, we invite you to explore selected works by Nobel laureates within the MDPI portfolio, and to join us in celebrating the global impact of their ideas.


The Nobel Prize in Physiology or Medicine 2025 has been awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for for their discoveries concerning peripheral immune tolerance. MDPI sincerely invites you to explore research in a related field.

 

 

The Science Behind the Prize: 2025 Nobel Physiology or Medicine Roundtable
6 October 2025, 03:30 pm (CEST)
You are welcome to watch the recording here!



The Nobel Prize in Physics 2025 has been awarded to John Clarke, Michel H. Devoret and John M. Martinis for the discovery of macroscopic quantum mechanical tunnelling and energy quantisation in an electric circuit. MDPI sincerely invites you to explore research in a related field.

 

 

The Science Behind the Prize: 2025 Nobel Physics Roundtable
7 October 2025, 02:30 pm (CEST)
You are welcome to watch the recording here!




The Nobel Prize in Chemistry 2025 has been awarded to Susumu Kitagawa, Richard Robson and Omar M. Yaghi for the development of metal-organic frameworks. MDPI sincerely invites you to explore research in a related field.

 

 

25 September 2025
Antibodies | Top 10 Cited Papers in 2024


1. “Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria”
by Lucas Jacobs, Nader Wauters, Yahya Lablad, Johann Morelle and Maxime Taghavi
Antibodies 2024, 13(1), 21; https://doi.org/10.3390/antib13010021
Available online: https://www.mdpi.com/2073-4468/13/1/21

2. “Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development”
by Tsvetelina Velikova, Metodija Sekulovski and Monika Peshevska-Sekulovska
Antibodies 2024, 13(1), 16; https://doi.org/10.3390/antib13010016
Available online: https://www.mdpi.com/2073-4468/13/1/16

3. “Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database”
by Connor Frey and Mahyar Etminan
Antibodies 2024, 13(3), 59; https://doi.org/10.3390/antib13030059
Available online: https://www.mdpi.com/2073-4468/13/3/59

4. “Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature”
by Maxime Taghavi, Abla Jabrane, Lucas Jacobs, Maria Do Carmo Filomena Mesquita, Anne Demulder and Joëlle Nortier
Antibodies 2024, 13(1), 1; https://doi.org/10.3390/antib13010001
Available online: https://www.mdpi.com/2073-4468/13/1/1

5. “Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management”
by Panagiotis Gklinos and Ruth Dobson
Antibodies 2024, 13(2), 43; https://doi.org/10.3390/antib13020043
Available online: https://www.mdpi.com/2073-4468/13/2/43

6. “A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments”
by Corrado Zengarini, Alba Guglielmo, Martina Mussi, Giovanna Motta, Claudio Agostinelli, Elena Sabattini, Bianca Maria Piraccini and Alessandro Pileri
Antibodies 2024, 13(2), 32; https://doi.org/10.3390/antib13020032
Available online: https://www.mdpi.com/2073-4468/13/2/32

7. “Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules”
by Francesco Ferrara, Chiara Verduci, Emanuela Laconi, Andrea Mangione, Chiara Dondi, Marta Del Vecchio, Veronica Carlevatti, Andrea Zovi, Maurizio Capuozzo and Roberto Langella
Antibodies 2024, 13(3), 76; https://doi.org/10.3390/antib13030076
Available online: https://www.mdpi.com/2073-4468/13/3/76

8. “Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature”
by Panagiotis Gklinos, Fotios Athanasopoulos, Vagia Giatrakou, Nikolaos-Achilleas Arkoudis, Dorothea Pournara, Eirini Giagkou, Argyro Tountopoulou, Sofia Vassilopoulou and Dimos-Dimitrios Mitsikostas
Antibodies 2024, 13(4), 79; https://doi.org/10.3390/antib13040079
Available online: https://www.mdpi.com/2073-4468/13/4/79

9. “A Comparison of Natural and Therapeutic Anti-IgE Antibodies”
by Monique Vogel and Paul Engeroff
Antibodies 2024, 13(3), 58; https://doi.org/10.3390/antib13030058
Available online: https://www.mdpi.com/2073-4468/13/3/58

10. “TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth”
by Amrendra K. Ajay, Martin Gasser, Li-Li Hsiao, Thomas Böldicke and Ana Maria Waaga-Gasser
Antibodies 2024, 13(1), 11; https://doi.org/10.3390/antib13010011
Available online: https://www.mdpi.com/2073-4468/13/1/11

3 September 2025
Join Us at the MDPI at the University of Toronto Career Fair, 23 September 2025, Toronto, ON, Canada


Date: 23 September 2025
Time: 11:00 a.m.–4:30 p.m
Location: The Chelsea Hotel, 33 Gerrard Street West, Toronto

MDPI is thrilled to announce our participation in the University of Toronto’s largest career fair, taking place at the St. George Downtown Campus. This exciting event brings together thousands of students, graduates, and professionals looking to connect with top employers and explore career opportunities.

We invite all attendees to visit the MDPI booth to discover how you can be part of one of the world’s leading open access academic publishers. Whether you are passionate about scientific research, editorial work, marketing, or supporting global innovation in publishing, we want to meet YOU!

What to expect at our booth:

  • Learn more about MDPI’s mission and global impact;
  • Explore exciting career opportunities in publishing, editorial, communications, and more;
  • Network with our team and ask questions about working at MDPI.

Whether you’re just starting your career or looking to take the next step, don’t miss this opportunity to connect with MDPI. Bring your resume, your curiosity, and your questions—we look forward to seeing you there!

For additional information on the Career Fair and Open MDPI positions, please visit the following links:

1 September 2025
MDPI INSIGHTS: The CEO's Letter #26 - CUJS, Head of Ethics, Open Peer Review, AIS 2025, Reviewer Recognition

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Society of China University Journals (CUJS) visit to MDPI Basel

In August, we had the pleasure of welcoming a delegation from the Society of China University Journals (CUJS) to our Basel headquarters. The visit was part of CUJS’s broader European tour, which included meetings with several major publishing organizations.

Purpose of the visit

The delegation’s stop in Basel involved an introductory meeting and knowledge-sharing with a view to identifying potential collaboration opportunities with MDPI. The CUJS team shared an overview of the Chinese scientific publishing landscape, including recent policy developments, and gave us insights into the journals and services they operate across China’s academic institutions.

MDPI presentations

We used the opportunity to introduce CUJS to MDPI’s mission, structure, and recent achievements. I presented on the latest developments at MDPI and our role in supporting global open access, addressing many follow-up questions from the delegation. Warm thanks are due to the following colleagues for their contributions to the session:

  • Liliane Auwerter (Conference Organizer, Scientific Officer and Sustainability Specialist) shared an overview of our editorial process, including the quality indicators we use to track peer-review performance.
  • Renato Merki (Publication Ethics Assistant) presented on behalf of our Research Integrity and Ethics team, emphasizing our commitment to responsible publishing.
  • Silvano Bonfatti (Product Manager) introduced the JAMS platform, highlighting how it supports efficient journal management for editors and publishers alike.
  • Aimar Xiong (Publisher, Section Managing Editor) and Giuliano Braccini (Office Manager) facilitated the meeting, offering clarity in response to specific questions, building the relationship during and beyond the meeting itself.

“Building relationships with organizations such as CUJS allows us to increase our visibility and reputation”

Why is this important?

China is one of the world’s largest producers of scientific research, with its universities and research institutes playing a key role in global scholarly publishing. Building strong relationships with influential organizations such as CUJS allows us to increase our visibility and reputation vis-à-vis the Chinese academic community, share best practices, learn from differing publishing models, and explore collaborations that have the potential to enhance the quality, reach, and diversity of our journals.

Looking ahead

It was a productive and friendly exchange that reflected our shared commitment to advancing scholarly communication and improving journal publishing practices. We value these visits, which allow us to create collaborations with stakeholders in the global academic community.

Our Basel office is a hub for hosting international delegations, partners, and collaborators. We look forward to creating more global connections that support our mission.

Impactful Research

Appointment of Dr. Tim Tait-Jamieson as Head of Publication Ethics

As part of our ongoing commitment to research integrity and publishing excellence, I am delighted to announce that we have appointed Dr. Tim Tait-Jamieson as Head of Publication Ethics.

In this role, Tim will lead the development of our ethics strategy and oversee the continued growth of the Publication Ethics Department, which is based across our offices in Basel, Manchester, Belgrade/Novi Sad, and Cluj. Guided by the principles of effective prevention and efficient resolution, the department plays an essential role in ensuring the highest standards of integrity throughout our editorial processes.

Department focus

Working closely with internal teams and external partners, the Publication Ethics Department focuses on refining our policies, aligning our operations with international best practices, and addressing complex cases with fairness and transparency. This work is critical in supporting our editors, reviewers, and authors, reinforcing MDPI’s contribution to the global dialogue on research integrity.

“Research integrity is something to which we all contribute through our daily work at MDPI”

About Tim

Tim joined MDPI in 2021 and has held several roles within the Publication Ethics Department, most recently serving as Research Integrity Lead. Based in our Basel office, he brings a strong academic background, with a Ph.D. in Geography from the University of Fribourg, Switzerland, and a proven track record of leadership in research integrity.

Research integrity is something to which we all contribute through our daily work at MDPI. I look forward to Tim’s leadership as we continue investing in the people, processes, and partnerships that uphold the trust and credibility of scholarly publishing.

Read more:

Inside MDPI

How and why MDPI offers Open Peer Review

At MDPI, we are committed to advancing openness and transparency in scholarly publishing. One area where we’ve taken a leadership role is peer review. Since 2014, MDPI has offered authors the option of open peer review, giving them the opportunity to publish reviewer comments alongside their papers. Each year, more authors are choosing this path, helping to build trust in the editorial process and provide valuable context for the research we publish.

Jack McKenna (Senior Content Specialist, MDPI) recently wrote an informative piece looking at the impact and importance of open peer review at MDPI. He highlights how this approach not only benefits readers but also gives well-deserved recognition to our reviewers, who generously dedicate their time and expertise to the academic community.

I encourage you to read this blogpost to see how MDPI is helping set standards for transparency in scholarly publishing.

Coming Together for Science

Recap of MDPI’s AIS 2025 Conference in Kuala Lumpur

Entering the month of August, we held The 2nd International Conference on AI Sensors and Transducers (AIS 2025) in Kuala Lumpur, Malaysia.

“AIS is quickly becoming a premier event in the field”

The second edition of AIS brought together 335 attendees from across Asia and beyond, including participants from China, Japan, Korea, and Southeast Asia. The event, chaired by Prof. Dr. Toshihiro Itoh (University of Tokyo), Prof. Dr. Sang-Woo Kim (Yonsei University), and Prof. Dr. Chengkuo Lee (National University of Singapore), continues to grow in reputation and has become an important platform for researchers and students to present their work, exchange ideas, and build international collaborations.

AIS is quickly becoming a premier event in the field, with participants highlighting its quality of service, its expanding academic network, and the value it delivers in the context of tightening research budgets in the region.

It was also excellent to see our new MDPI journal AI Sensors, which originated from a conference topic, host a successful launch party at the event.

Highlights from participant feedback:

  • Southeast University (China) sent a student delegation and considers AIS a regular fixture for Ph.D. students in need of international conference experience.
  • CAS Aerospace Information Research Institute sent a 10-member delegation and plans to further promote AIS internally.
  • Japanese researchers regard AIS as a must-attend event, placing it on a par with IEEE conferences and citing the benefits of networking and exchange.
  • Korean academics praised the organization and noted improved perceptions of MDPI among their institutions, viewing AIS as a strategic opportunity to deepen engagement in the region.

Award winners

We recognized the recipients of the Best Presentation, Best Scientist, Best Poster, and Best Student Paper awards, whose contributions set a standard for academic excellence. The full award announcement is available here.

Looking ahead

The 3rd International Conference on AI Sensors and Transducers will be held from 5 to10 August 2026 in Jeju, Korea. The General Chairs will be Prof. Inkyu Park (Korea Advanced Institute of Science and Technology), Prof. Zhou Li (Tsinghua University), Prof. Xinge Yu (City University of Hong Kong), and Prof. Chengkuo Lee (National University of Singapore). We look forward to bringing together innovators, researchers and experts who are shaping the future at the intersection of sensors, sensing technology, transducers and artificial intelligence.

Thank you

Our conference team managed this event with great agility and professionalism and are already planning improvements to make the conference even more accessible. Special thanks to the National University of Singapore for their support, and to our entire conference team and collaborators for their dedication.

AIS is gaining momentum, and we look forward to supporting its role as a bridge between MDPI and the global academic community.

“Our conference team managed this event with great agility and professionalism”

Closing Thoughts

Recognizing our outstanding reviewers

As we close this edition of the newsletter, I would like to spotlight MDPI’s 2024 Outstanding Reviewer Awards, which showcase a group of winners whose contributions often go unseen but are essential to the integrity of scholarly publishing: our reviewers.

In 2024, more than 215,000 reviewers dedicated their time and expertise to MDPI journals. From this community, we are proud to recognize 356 recipients of the Outstanding Reviewer Awards, who went above and beyond by providing timely, thorough and constructive feedback.

These awards are not only a token of our appreciation but also a reflection of the values we stand for: rigor, fairness and collaboration in advancing science.

To explore the full list of awardees across disciplines, from life sciences to the humanities, please visit the following pages:

About MDPI Awards

To recognize the academic community, MDPI journals regularly offer various awards to researchers in specific fields. Serving as a source of recognition and inspiration, these awards help increase the influence of scholars who have been credited with outstanding achievements and are making a significant contribution to the advancement of their respective fields.

To explore more opening Outstanding Reviewer Awards, please click here.

To all our reviewers: thank you for being the foundation of trust that makes open access publishing possible!

Stefan Tochev
Chief Executive Officer
MDPI AG

20 August 2025
Antibodies | Issue Cover Collection Published in 2023

1. “Characterization of Active MMP9 in Chronic Inflammatory Diseases Using a Novel Anti-MMP9 Antibody”
by Maile Velasquez, Chris O’Sullivan, Robert Brockett, Amanda Mikels-Vigdal, Igor Mikaelian, Victoria Smith and Andrew E. Greenstein
Antibodies 2023, 12(1), 9; https://doi.org/10.3390/antib12010009
Available online: https://www.mdpi.com/2073-4468/12/1/9

Cover Story: Matrix metalloproteinase 9 (MMP9), a protease implicated in multiple diseases, is secreted as an inactive zymogen and requires proteolytic removal of the pro-domain for activation. The relative levels and functionality of the pro- and active-MMP9 isoforms in tissues are not characterized. We generated a specific antibody that distinguishes an active form of MMP9, F107-MMP9, from the inactive pro-MMP9 isoform. Using multiple in vitro assays and specimen types, we show that F107-MMP9 expression is localized and disease-specific compared with its more abundant parental pro-form. It is detected around sites of active tissue remodeling, including fistulae of inflammatory bowel and dermal fissures in hidradenitis suppurativa, and is expressed by myeloid cells, including macrophages and neutrophils.

2. “CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases”
by Sara Gómez-Melero and Javier Caballero-Villarraso
Antibodies 2023, 12(2), 30; https://doi.org/10.3390/antib12020030
Available online: https://www.mdpi.com/2073-4468/12/2/30

Cover Story: The CC chemokine receptor 6 (CCR6) is a G protein-coupled receptor (GPCR) involved in a wide range of biological processes. When CCR6 binds to its sole ligand CCL20, a signaling network is produced. This pathway is implicated in mechanisms related to many diseases, such as cancer, psoriasis, multiple sclerosis, HIV infection or rheumatoid arthritis. The CCR6/CCL20 axis plays a fundamental role in immune homeostasis and activation. Th17 cells express the CCR6 receptor and inflammatory cytokines, including IL-17, IL-21 and IL-22, which are involved in the spread of inflammatory response. The CCL20/CCR6 mechanism plays a crucial role in the recruitment of these pro-inflammatory cells to local tissues.

3. “Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy”
by Christopher Chung, Sagar B. Kudchodkar, Curtis N. Chung, Young K. Park, Ziyang Xu, Norbert Pardi, Mohamed Abdel-Mohsen and Kar Muthumani
Antibodies 2023, 12(3), 46; https://doi.org/10.3390/antib12030046
Available online: https://www.mdpi.com/2073-4468/12/3/46

Cover Story: Harnessing the immune system to combat disease has revolutionized medical treatment. Monoclonal antibodies (mAbs), in particular, have emerged as important immunotherapeutic agents with clinical relevance in treating a wide range of diseases, including allergies, autoimmune diseases, neurodegenerative disorders, cancer, and infectious diseases. These mAbs are developed from naturally occurring antibodies and target specific epitopes of single molecules, minimizing off-target effects. Antibodies can also be designed to target particular pathogens or modulate immune function by activating or suppressing certain pathways. Despite the benefit for patients, the production and administration of monoclonal antibody therapeutics are laborious, costly, and time-consuming.

4. “Antibody Cross-Reactivity in Serodiagnosis of Lyme Disease”
by Weronika Grąźlewska and Lucyna Holec-Gąsior
Antibodies 2023, 12(4), 63; https://doi.org/10.3390/antib12040063
Available online: https://www.mdpi.com/2073-4468/12/4/63

Cover Story: Lyme disease is a tick-borne disease caused by spirochetes belonging to the Borrelia burgdorferi sensu lato complex. The disease is characterized by a varied course; therefore, the basis for diagnosis is laboratory methods. Currently, a two-tiered serological test is recommended, using an ELISA as a screening test and a Western blot as a confirmatory test. This approach was introduced due to the relatively high number of false-positive results obtained when using an ELISA alone. However, this approach has not entirely solved the problem of false-positive results caused by cross-reactive antibodies. Many highly immunogenic B. burgdorferi s.l. proteins are recognized nonspecifically by antibodies directed against other pathogens.

20 August 2025
Antibodies | Notable Review Papers Published in 2023–2024


Given that all articles published in Antibodies (ISSN: 2073-4468) are freely available in an open access format, we welcome you to read our notable review papers published in 2023 and 2024.

1. “CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases”
by Sara Gómez-Melero and Javier Caballero-Villarraso
Antibodies 2023, 12(2), 30; https://doi.org/10.3390/antib12020030
Available online: https://www.mdpi.com/2073-4468/12/2/30

2. “Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria”
by Lucas Jacobs, Nader Wauters, Yahya Lablad, Johann Morelle and Maxime Taghavi
Antibodies 2024, 13(1), 21; https://doi.org/10.3390/antib13010021
Available online: https://www.mdpi.com/2073-4468/13/1/21

3. “A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)”
by Kristin Widyasari and Jinnam Kim
Antibodies 2023, 12(1), 5; https://doi.org/10.3390/antib12010005
Available online: https://www.mdpi.com/2073-4468/12/1/5

4. “Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy”
by Christopher Chung, Sagar B. Kudchodkar, Curtis N. Chung, Young K. Park, Ziyang Xu, Norbert Pardi, Mohamed Abdel-Mohsen and Kar Muthumani
Antibodies 2023, 12(3), 46; https://doi.org/10.3390/antib12030046
Available online: https://www.mdpi.com/2073-4468/12/3/46

5. “Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier”
by Toshihiko Tashima
Antibodies 2023, 12(3), 43; https://doi.org/10.3390/antib12030043
Available online: https://www.mdpi.com/2073-4468/12/3/43

6. “Non-Affinity Purification of Antibodies”
by Tsutomu Arakawa, Yui Tomioka, Masataka Nakagawa, Chiaki Sakuma, Yasunori Kurosawa, Daisuke Ejima, Kouhei Tsumoto and Teruo Akuta
Antibodies 2023, 12(1), 15; https://doi.org/10.3390/antib12010015
Available online: https://www.mdpi.com/2073-4468/12/1/15

7. “New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond”
by Marino Paroli, Chiara Gioia and Daniele Accapezzato
Antibodies 2023, 12(1), 25; https://doi.org/10.3390/antib12010025
Available online: https://www.mdpi.com/2073-4468/12/1/25

8. “IgA Nephropathy: Current Treatment and New Insights”
by Dimitra Petrou, Petros Kalogeropoulos, George Liapis and Sophia Lionaki
Antibodies 2023, 12(2), 40; https://doi.org/10.3390/antib12020040
Available online: https://www.mdpi.com/2073-4468/12/2/40

9. “Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature”
by Maxime Taghavi, Abla Jabrane, Lucas Jacobs, Maria Do Carmo Filomena Mesquita, Anne Demulder and Joëlle Nortier
Antibodies 2024, 13(1), 1; https://doi.org/10.3390/antib13010001
Available online: https://www.mdpi.com/2073-4468/13/1/1

10. “Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management”
by Panagiotis Gklinos and Ruth Dobson
Antibodies 2024, 13(2), 43; https://doi.org/10.3390/antib13020043
Available online: https://www.mdpi.com/2073-4468/13/2/43

31 July 2025
MDPI INSIGHTS: The CEO's Letter #25 - 8,000 Staff Worldwide, Korea Visit, 100,000 Preprints, Malaysia Roundtable, Canada Consortium Deal

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Talent Drives Our Progress

For the first time in MDPI’s history, we now have over 8,000 colleagues across the company. I would like to take a moment to celebrate this milestone and acknowledge the driving force behind our growth and success: our people.

As the world’s leading fully open access publisher, MDPI has grown thanks to the dedication, talent, and teamwork of colleagues across the company. Already halfway through 2025, we’ve welcomed nearly 2,000 new colleagues. 

“Our achievements are also about the people behind them”

We now manage over 475 journals, with 298 receiving an Impact Factor, and hundreds more indexed in major databases, including 343 in Scopus, and 92 by PubMed. As the reach and impact of our journals continues to grow, so does the need for dedicated and qualified teams to support that growth. Thus, attracting and retaining exceptional talent remains a cornerstone of our success.

Our achievements are not just about the results of journal expansion, however: they’re about the people behind them. From our hardworking editors to our meticulous English editing and production teams – from our journal relationship specialists, public relations, marketing and communications professionals to our conference teams and the project teams behind Preprints, Scilit, SciProfiles, JAMS and more. Our success reflects the work of thousands of people showing up each day, taking pride in their work, and committed to excellence and service.

What we’re doing to support talent:

  • Investing in onboarding and training to help new colleagues feel welcomed and empowered to thrive.
  • Creating clearer career paths across all functions, from editorial to communications and beyond.
  • Launching mentorship programs and internal knowledge-sharing sessions to promote growth and collaboration.
  • Evolving our recognition and rewards programs to better celebrate your contributions.
  • Expanding our training systems and platforms.

MDPI’s in-house training department offers over 215 training courses, covering topics from editorial development to cross-cultural collaboration. In 2024 alone, we had 44 full-time trainers and 196 part-time training assistants supporting the learning and development needs of colleagues worldwide. These efforts ensure our teams are equipped with the skills and confidence to grow professionally and contribute meaningfully.

Over two-thirds of our workforce is editorial, and of our more than 5,400 editors, 87% hold a Master’s degree and 6% a PhD. Their collective contributions are central to delivering a high-quality publishing experience and supporting global academic communication.

As we celebrate this milestone, we also aim to continue on a path of steady and sustainable growth, one that balances journal expansion with investment in people, outreach, processes, and innovation. Together, we are shaping the future of open access and academic publishing. Thank you for your hard work, your ideas, and your commitment to serving the global research community.

Let’s continue working together to create a culture where great talent grows and every colleague feels valued.

Impactful Research

Visiting South Korea: Building Connections and Supporting the MDPI Seoul Office

In July, I had the opportunity to visit our team in Seoul and engage directly with academic communities in South Korea. The visit focused on deepening MDPI’s relationships with local universities, institutions, and partners, and supporting the great work of our colleagues at the MDPI Seoul office.

Korea Association of Private University Libraries (KAPUL) Conference

A highlight of the visit was our participation in the Korea Association of Private University Libraries (KAPUL) Conference, where we presented to over 100 academic librarians. I delivered a keynote speech titled “The Evolving Publishing Landscape: Open Access and Beyond,” while my colleague Dr. Jisuk Kang (Public Affairs Specialist) shared insights in her presentation, “Inside MDPI: Editorial Practices & Research Integrity.”

Facts & Figures: South Korea

  • South Korea is MDPI’s sixth-largest publishing country by article volume (over 90,000 MDPI papers published to date).
  • In 2024, Korea ranked 16th globally by total publications, and 6th (among these top 20 countries) by citation impact.
  • 52% of Korean publications in 2024 were OA – and 73% of those were Gold OA.
  • MDPI published about 20% of all OA papers from Korea in 2024.
  • Over 2,000 active Editorial Board Members from South Korea contribute to MDPI journals, with 11 Section Editors-in-Chief.
  • We currently have 11 Institutional Open Access Program agreements and two society partnerships in Korea:
    • Korean Society of Pharmaceutical Sciences and Technology (with MDPI journal Pharmaceutics)
    • Korean Tribology Society (with MDPI journal Coatings)

MDPI Seoul Office and the First Korea Salon

Our Seoul office serves as a regional hub for marketing, communications, and community engagement. It continues to grow in size and influence, prioritizing supporting scholar visits, conference sponsorships, and outreach events such as the recent MDPI Korea Salon.

The inaugural Salon, themed “Exploring Research Trends in Medical Publishing, Ethics, and AI,” brought together over 20 scholars and Editorial Board members serving MDPI journals.

Thank you to our guest speakers including Professors Young-Joon Surh of Seoul National University, Kwang-Sig Lee of Korea University, and Jin-Won Noh of Yonsei University who presented on the landscape of medicine in South Korea and across the globe. The Salon also included presentations from MDPI colleagues on Open Access, ethics, and how the IOAP can support researchers in this field.

“Our Seoul office continues to grow in size and influence”

Looking Ahead

MDPI is already the leading OA publisher in South Korea, yet challenges and misconceptions around OA and APCs remain. Visits like this one, along with the ongoing efforts of our Seoul office, are important to building understanding, trust, and long-term relationships with the local academic community.

A big thank-you to our colleagues in Seoul for their warm hospitality, professionalism, and energy! Our new office is well situated, staffed, and ready to grow. This visit marked an important step forward in our continued mission to support global research communities and advance Open Science.

Inside MDPI

Preprints.org Reaches 100,000 Preprints: A Major Milestone for MDPI and Open Science

In case you missed it, Preprints.org recently surpassed 100,000 preprints posted. This is a major milestone for our platform and one worth celebrating.

Preprints are a key pillar of the Open Science movement, which promotes transparency, equity, and faster knowledge-sharing through initiatives such as Open Access, Open Data, Open Source, and Open Peer Review. The benefits of Open Science extend beyond researchers, as they support funders, educators, policymakers, and the public in advancing discovery and innovation.

What is behind the 100,000 preprints milestone?

Since its launch in 2016, Preprints.org has grown into one of the world’s leading preprint platforms, now ranked fifth globally by publication volume.

More than 350,000 researchers have contributed, helping shape this dynamic and collaborative space for sharing early-stage research across all disciplines.

Read the full announcement here:
https://www.mdpi.com/about/announcements/12202

“Preprints.org has grown into one of the world’s leading preprint platforms”

Some quick facts worth noting:

  • About 56% of the preprints on Preprints.org are later published in peer-reviewed journals.
  • The platform is now indexed in Web of Science (Preprint Citation Index), Europe PMC, and Crossref, helping improve visibility and trust in the preprints shared.
  • Recent upgrades – including a revamped website, new features such as search subscriptions, curated reading lists, and community feedback tools (PREreview) – show our commitment to developing Preprints.org in line with researchers’ needs.

This growth and progress would not be possible without the dedication of the Preprints.org team, our Advisory Board members, screeners, and colleagues across MDPI who support the platform’s development. This milestone is a reminder of our shared mission: to accelerate scientific communication and build a more open, transparent, and inclusive research ecosystem.

I’m excited to see what’s ahead as we approach Preprints.org’s 10-year anniversary in 2026!

Coming Together for Science

Malaysia Media Roundtable: Educating on Open Access and MDPI’s Presence in Southeast Asia

At the end of June, I had the opportunity to participate in a strategic media roundtable in Kuala Lumpur, focused on raising awareness about the importance of Open Access (OA) and on MDPI’s growing presence in Southeast Asia.

We welcomed five Malaysian media outlets for an engaging private session that included presentations and open discussion.

I gave an overview of the benefits of Open Access, MDPI’s global developments, and our collaborations in Malaysia.

My colleague Yu Nwe Soe (Public Relations Specialist), presented on our editorial process, helping to clarify how MDPI supports authors and maintains research quality.

We were also joined by two local Editorial Board Members (EBMs) who offered first-hand insights into their experiences working with MDPI and how OA has shaped their publishing choices.

The discussion covered a range of questions from the press, from OA publishing models to editorial standards, and highlighted MDPI’s unique contribution to accelerating scientific communication in the region.

As the leading fully OA publisher, we see it as our responsibility to continue educating research communities and the broader public on the impact of OA, especially in emerging and high-growth academic markets.

Spotlight on Malaysia

Malaysia continues to rise as a regional research hub, with five universities ranked in the global top 200 and 11 subjects in the global top 50. In 2024, Malaysia ranked 2nd in Southeast Asia in total publication output, 10th in Asia, and 25th globally.

MDPI’s presence in Malaysia:

  • Over 21,000 research articles published to date from Malaysian institutions
  • More than 1,100 articles published in 2024 alone
  • In the period 2020–2024, 54% of Malaysia’s total publications were OA
  • 36 EBMs from Malaysia, across 27 MDPI journals
  • Around 100 conferences sponsored in Malaysia in the past five years
  • MDPI is hosting the 2nd International Conference on AI Sensors and Transducers in Kuala Lumpur (29 July- 3 August 2025)

Media Coverage & Editorial Voices

Following the roundtable, we saw positive coverage across several local outlets, with articles highlighting MDPI’s role in empowering Malaysian researchers. Notable pieces included:

Our local EBMs also shared their perspectives:

Prof. Denny Ng Kok Sum (Sunway University, EBM of MDPI journal Processes) and Prof. Lee (EBM of MDPI journal Bacteria) share their experiences with MDPI and the role Open Access plays in their publication decisions.

“We see it as our responsibility to continue educating research communities on the impact of OA”

“I didn’t want my work stuck behind a paywall.”
— Prof. Denny Ng Kok Sum, Sunway University, Processes Editorial Board Member

“Open Access opens doors for collaboration and visibility, especially in fast-developing regions like ours.”
— Prof. Lee, Bacteria Editorial Board Member

This roundtable marked another step in building trust, understanding, and collaboration in Southeast Asia. A big thank-you to the MDPI Malaysia team and all those who contributed to the event’s success.

Closing Thoughts

MDPI Signs First North American Agreement with Canadian Consortium

We are proud to announce a major milestone for MDPI Canada and an important step forward for OA in North America.

In July, our Toronto office finalized MDPI’s first North American consortium agreement with the Federal Science Libraries Network (FSLN). This is a significant achievement that strengthens our expansion in Canada and reinforces our global commitment to supporting Open Science.

This two-year agreement gives Canadian federal agencies access to MDPI’s IOAP, including discounted article processing charges for affiliated researchers across our portfolio of over 475 OA journals. It lowers barriers for Canadian scientists to share their work more openly and reach a global audience.


Ryan Siu, Institutional Partnerships Manager at MDPI.

“The Open Science landscape in Canada is rapidly evolving, with the Tri-Agency Open Access Policy set for renewal by the end of 2025. This reflects ongoing efforts to foster greater scientific transparency and accessibility at a national policy level,” says Ryan Siu, Institutional Partnerships Manager at MDPI.

“Our new agreement with FSLN represents our shared commitment to further these efforts and foster wider readership. By aligning with these initiatives, we make progress towards research that’s both inclusive and impactful, benefiting local and global communities alike.”

Participating FSLN institutions include:

  • Agriculture and Agri-Food Canada
  • Environment and Climate Change Canada
  • Health Canada
  • National Research Council Canada
  • Natural Resources Canada

By partnering with some of Canada’s largest science-based agencies, we reaffirm our goal of advancing OA across continents. We look forward to developing our support for Canadian researchers and continuing to drive progress in Open Science across North America and beyond.

Stefan Tochev
Chief Executive Officer
MDPI AG

29 July 2025
Meet Us at the 5th International Symposium on Frontiers in Molecular Science, 26–29 August 2025, Kyoto, Japan


The 5th International Symposium on Frontiers in Molecular Science (ISFMS2025), organized by the International Journal of Molecular Sciences (ISSN: 1422-0067) and MDPI, will be held from 26 to 29 August 2025 in Kyoto, Japan.

This conference will present outstanding research results that elucidate the molecular mechanisms of biological functions and regulation and will also facilitate drug design based on molecular biology, biophysical characterization, in vivo environmental homeostasis, organ interactions based on sensory systems, the physiome, and AI-assisted analysis of protein structures and functions. It aims to bring together scientists, researchers, and engineers from across the world who are working in academia, national labs, and industry to discuss the latest advances in molecular science.

Topics that will be covered include, but are not limited to, the following:

  • Protein structure and function;
  • Multidomain proteins;
  • Drug design and drug resistance;
  • Enzymes;
  • Molecular biology of galectins;
  • Glycobiophysics;
  • NMR spectroscopy;
  • Specific sensory systems;
  • Brain and systemic function.

The following MDPI journals will be represented at this conference:

  • International Journal of Molecular Sciences;
  • Current Issues in Molecular Biology;
  • Cells;
  • Bioengineering;
  • Biophysica;
  • BioTech;
  • Cancers;
  • International Journal of Translational Medicine;
  • Kinases and Phosphatases;
  • Microorganisms;
  • Molecules;
  • Synbio;
  • Antibiotics;
  • Antioxidants;
  • Applied Biosciences;
  • BioMed;
  • Biomedicines;
  • BioMedInformatics;
  • Membranes;
  • Antibodies.

If you are planning to attend this conference, please feel free to reach out online and start a conversation with us. Our delegates look forward to meeting you in person at our booth and answering any questions you may have. For more information about this event, please click on the following link:  https://sciforum.net/event/ISFMS2025.

29 July 2025
Antibodies | Exclusive Interview with Prof. Dr. Traian Sulea—Session 1 Chair of the 1st International Online Conference by Antibodies


With a strong background in bio, organic, and physical chemistry, I am an established computational chemist with over 25 years of experience and broad expertise in molecular modeling applied to (bio)pharmaceutical research; ranging from cheminformatics-based small-molecule lead discovery and optimization to structural bioinformatics-based computational biology, and from molecular simulations of protein-ligand complexes to engineering of therapeutic proteins and antibody humanization.

Name: Prof. Dr. Traian Sulea
Affiliation: National Research Council Canada, Montreal, Canada
Research interests: health, biotechnology, biotherapeutics, chemistry, information technology, modelling software

The following is a short interview with Prof. Dr. Traian Sulea:

  1. Could you please briefly introduce yourself?

I am the Principal Research Officer and Team Leader of Molecular Modeling at the National Research Council Canada, which I joined as a post-doctoral fellow in 1995. I have also been an Adjunct Professor at the Institute of Parasitology of McGill University since 2012, where I teach structural bioinformatics and therapeutic antibody design. My expertise in applying computational approaches to the discovery and optimization of bioactive small-molecules and biologics includes the development of computational methods for biomolecular applications with a focus on continuum solvation and binding affinity predictions, structure-based engineering of protein fusions, selective targeting of solid tumor microenvironment, and antibody optimization via humanization, affinity maturation, selective conjugation, and developability assessment. I have authored over 150 publications, including 110 peer-reviewed articles, 38 international patents, and 5 book chapters.

  1. What do you think of the development status and trends of open access publishing?

Huge strides have been made in making scientific research widely accessible to everyone. More and more scientific studies and associated data are freely available, and I believe this trend will continue. Peer-reviewing is also an important process of scientific publishing, and much debate has been shared lately on the quality of this process, which can certainly benefit from fine-tuning and improvement, perhaps also via adding a component involving a wider community-based evaluation of submitted papers.

  1. What is your impression of the Antibodies journal?

Antibodies is a journal addressing a niche area of research that lacks sufficient publishing venues. With a relatively well-reputed history and track record, it definitely has huge potential to become one of the leading journals in this field of antibody research, where both fundamental and applied science can find their homes.

  1. What do you think will be the research hotspots in the field of antibodies in the next few years, and can you describe them to us?

I think that even higher-throughput methods for screening even larger antibody libraries will always be in vogue in the field of antibody discovery, characterization, and optimization towards drug candidates with unparalleled medical benefits. As a molecular modeler and computational structural biologist, I am in awe of the latest advances in antibody structure prediction methods, and so I am certain computational methods based on artificial intelligence and deep learning from large datasets will be the next hotspot of this field for the next while.

  1. Can you give any advice on academic research for young scholars in related fields?

Emerging young scientists should get involved in the field of therapeutic antibody engineering and pay particular attention to the fast-paced developments in artificial intelligence, which are on the verge of reshaping the discovery and optimization of antibody drugs in the near future.

  1. Could you kindly share with us your thoughts and outlook on this E-conference?

I believe this is a timely conference in the field of therapeutic antibody discovery and development. I hope the research presented throughout the conference will be positioned at the forefront of the field and, therefore, able to spur much interest and further advances. It also has the potential to boost the visibility of the Antibodies journal to the relevant audience. The organizing committee has assembled an excellent team of high-profile scientists serving in various roles, like conference and session chairs, as well as selection committee members, and has been able to invite renowned scientists to deliver keynote lectures and oral presentations. It is my belief that this first edition will serve as a stepping stone towards defining this conference as a must-attend event in the future.

  1. Could you please provide a brief introduction to the session you are chairing, titled “Computational Antibody Engineering”?

In silico design and optimization of antibodies for therapeutic applications has gained significant traction in the past decade. It builds on the solid foundation established for classical methods in protein structure-based modeling, combined with the recent breakthrough of artificial intelligence in protein structure prediction. Recognition of these achievements in 2024 by the Nobel Prize in Chemistry demonstrated the value carried by these computational protein engineering methods, with far-reaching potential practical applications in therapeutic antibody discovery and development. This timely session thus welcomes contributions describing the latest refinements of established classical physics-based computational methods as well as the recent developments of rapidly evolving artificial intelligence-based approaches. Presentations will cover computational predictions of antibody–antigen binding affinity, specificity, docking and epitope mapping, predictions of antibody biophysical properties such as stability, aggregation, and immunogenicity, design and triage of antibody libraries for hit enrichment and downstream manufacturability, molecular engineering of novel antibody modalities, and entirely in silico antibody discovery efforts.

Back to TopTop